Kombinationen af indacaterol/glycopyrronium til KOL har effekt på symptomer, FEV1 og eksacerbationer

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Kombinationen af indacaterol/glycopyrronium til KOL har effekt på symptomer, FEV1 og eksacerbationer. / Ulrik, Charlotte Suppli.

In: Ugeskrift for Laeger, Vol. 176, No. 38, 15.09.2014, p. 2-6.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Ulrik, CS 2014, 'Kombinationen af indacaterol/glycopyrronium til KOL har effekt på symptomer, FEV1 og eksacerbationer', Ugeskrift for Laeger, vol. 176, no. 38, pp. 2-6.

APA

Ulrik, C. S. (2014). Kombinationen af indacaterol/glycopyrronium til KOL har effekt på symptomer, FEV1 og eksacerbationer. Ugeskrift for Laeger, 176(38), 2-6.

Vancouver

Ulrik CS. Kombinationen af indacaterol/glycopyrronium til KOL har effekt på symptomer, FEV1 og eksacerbationer. Ugeskrift for Laeger. 2014 Sep 15;176(38):2-6.

Author

Ulrik, Charlotte Suppli. / Kombinationen af indacaterol/glycopyrronium til KOL har effekt på symptomer, FEV1 og eksacerbationer. In: Ugeskrift for Laeger. 2014 ; Vol. 176, No. 38. pp. 2-6.

Bibtex

@article{6cca3d1f291d42b891837af1ac3aff6d,
title = "Kombinationen af indacaterol/glycopyrronium til KOL har effekt p{\aa} symptomer, FEV1 og eksacerbationer",
abstract = "Long-acting bronchodilators are the mainstay of pharmacological therapy for chronic obstructive pulmonary disease (COPD). This paper reviews the efficacy of the once-daily fixed-dose dual bronchodilator combination of indacaterol and glycopyrronium in COPD patients. Compared with single therapy with indacaterol, glycopyrronium and tiotropium and fixed combination salmeterol/fluticasone, fixed-dose indacaterol/glycopyrronium has clinically relevant effects on symptoms, health status, lung function, and rate of exacerbations and by that suggests a potential for dual bronchodilation as an important maintenance therapeutic option for some patients with COPD.",
author = "Ulrik, {Charlotte Suppli}",
year = "2014",
month = sep,
day = "15",
language = "Dansk",
volume = "176",
pages = "2--6",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "38",

}

RIS

TY - JOUR

T1 - Kombinationen af indacaterol/glycopyrronium til KOL har effekt på symptomer, FEV1 og eksacerbationer

AU - Ulrik, Charlotte Suppli

PY - 2014/9/15

Y1 - 2014/9/15

N2 - Long-acting bronchodilators are the mainstay of pharmacological therapy for chronic obstructive pulmonary disease (COPD). This paper reviews the efficacy of the once-daily fixed-dose dual bronchodilator combination of indacaterol and glycopyrronium in COPD patients. Compared with single therapy with indacaterol, glycopyrronium and tiotropium and fixed combination salmeterol/fluticasone, fixed-dose indacaterol/glycopyrronium has clinically relevant effects on symptoms, health status, lung function, and rate of exacerbations and by that suggests a potential for dual bronchodilation as an important maintenance therapeutic option for some patients with COPD.

AB - Long-acting bronchodilators are the mainstay of pharmacological therapy for chronic obstructive pulmonary disease (COPD). This paper reviews the efficacy of the once-daily fixed-dose dual bronchodilator combination of indacaterol and glycopyrronium in COPD patients. Compared with single therapy with indacaterol, glycopyrronium and tiotropium and fixed combination salmeterol/fluticasone, fixed-dose indacaterol/glycopyrronium has clinically relevant effects on symptoms, health status, lung function, and rate of exacerbations and by that suggests a potential for dual bronchodilation as an important maintenance therapeutic option for some patients with COPD.

M3 - Tidsskriftartikel

C2 - 25294211

VL - 176

SP - 2

EP - 6

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 38

ER -

ID: 137370228